# The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

> **NCT07134205** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 252 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** JMT101
- **DRUG:** Irinotecan
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT07134205
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134205, "The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07134205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*